Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 686-696

  Cambau, E ^a   Viveiros, M ^c   Machado, D ^b   Raskine, L ^a   Ritter, C ^c   Tortoli, E ^d   Matthys, V ^e   Hoffner, S ^f,g   Richter, E ^h   Perez Del Molino, M L ⁱ   Cirillo, D M ^d   Van Soolingen, D ^j,k   Bottger E C ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

^h RESEARCH CENTER BORSTEL   (Germany)

ⁱ UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Antibiotic susceptibility testing; Antituberculous drugs; DST; MGIT; TB eXiST

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GROWTH CURVE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUANTITATIVE ANALYSIS; CLINICAL TRIAL; DRUG EFFECTS; EUROPE; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PROCEDURES; STANDARDS;

ANTITUBERCULAR AGENTS; EUROPE; GENOTYPING TECHNIQUES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84928183832     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku438     Document Type: Article

References (51)

1. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
2. ECDC/WHO Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe 2014. Stockholm: ECDC, 2014.
3. Dheda K, Gumbo T, Gandhi NR et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2013; 2: 321-38.
4. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-45.
5. Quy HT, Lan NT, Borgdorff MWet al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-6.
6. Burman WJ. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci 1997; 313: 355-63.
7. Pietersen E, Ignatius E, Streicher EM et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-9.
8. WHO. Guidelines for the Programmatic Management of Multidrug Resistant Tuberculosis. Geneva: WHO, 2011.
9. Flament-Saillour M, Robert J, Jarlier V et al. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999; 160: 587-93.
10. Drobniewski F, Eltringham I, Graham C et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002; 57: 810-6.
11. Turett GS, Telzak EE, Torian LV et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238-44.
12. Johnston JC, Shahidi NC, Sadatsafavi M et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
13. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-81.
14. Cambau E, Rush-Gerdes S. First and second line susceptibility testing for Mycobacterium tuberculosis complex. In: ECDC, ed. Mastering the Basics of Tuberculosis Control: Development of a Handbook on TB Diagnostic Methods. Stockholm: ECDC, 2011; 79-87.
15. Drobniewski F, Rusch-Gerdes S, Hoffner S. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1)- report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 2007; 13: 1144-56.
16. Streicher EM, Muller B, Chihota V et al. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol 2011; 12: 686-94.
17. Martin A, Imperiale B, Ravolonandriana P et al. Prospective multicentre evaluation of the direct nitrate reductase assay for the rapid detection of extensively drug-resistant tuberculosis. J Antimicrob Chemother 2014; 69: 441-4.
18. Fitzwater SP, Sechler GA, Jave O et al. Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay. Eur Respir J 2012; 41: 1163-71.
19. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
20. Bernard C, Brossier F, SougakoffWet al. A surge of MDR and XDR tuberculosis in France among patients born in the former Soviet Union. Euro Surveill 2013; 18: pii1/420555.
21. Perdigao J, Macedo R, Silva C et al. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. J Antimicrob Chemother 2012; 68: 27-33.
22. Cambau E, Truffot-Pernot C, Boulahbal F et al. Mycobacterial growth indicator tube versus the proportion method on Lowenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 2000; 19: 938-42.
23. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-40.
24. Brossier F, Veziris N, Aubry A et al. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
25. Ritter C, Lucke K, Sirgel FA et al. Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains. J Clin Microbiol 2014; 52: 940-6.
26. Bemer P, Palicova F, Rusch-Gerdes S et al. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150-4.
27. Rodrigues C, Jani J, Shenai S et al. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 2008; 12: 1449-55.
28. Springer B, Lucke K, Calligaris-Maibach R et al. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-80.
29. Schon T, Jureen P, Chryssanthou E et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15: 502-9.
30. Angeby KA, Jureen P, Giske CG et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010; 65: 946-52.
31. Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-34.
32. Folkvardsen DB, Svensson E, Thomsen VO et al. Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J Clin Microbiol 2013; 51: 1596-9.
33. Streicher EM, Bergval I, Dheda K et al. Mycobacterium tuberculosis population structure determines the outcome of genetics-based secondline drug resistance testing. Antimicrob Agents Chemother 2012; 56: 2420-7.
34. Mathys V, Wintjens R, Lefevre P et al. Molecular genetics of paraaminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53: 2100-9.
35. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92: 687-703.
36. Canetti G, Froman S, Grosset J et al. Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull World Health Organ 1963; 29: 565-78.
37. Mitchison DA. What is drug resistance? Tubercle 1969; 50: Suppl: 44-7.
38. Banfi E, Scialino G, Monti-Bragadin C. Development of a microdilution method to evaluate Mycobacterium tuberculosis drug susceptibility. J Antimicrob Chemother 2003; 52: 796-800.
39. Katiyar SK, Bihari S, Prakash S et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 139-45.
40. van Ingen J, Aarnoutse R, de Vries G et al. Low-level rifampicinresistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int J Tuberc Lung Dis 2011; 15: 990-2.
41. Maruri F, Sterling TR, Kaiga AW et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819-31.
42. Fillion A, Aubry A, Brossier F et al. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother 2013; 57: 4496-500.
43. Yang B, Koga H, Ohno H et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-8.
44. Sirgel FA, Warren RM, Bottger EC et al. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 2013; 8:e59414.
45. Grau T, Selchow P, Tigges M et al. Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 1142-5.
46. Willand N, Dirie B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009; 15: 537-44.
47. Petrella S, Gelus-Ziental N, Maudry A et al. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 2011; 6:e15785.
48. Brossier F, Veziris N, Truffot-Pernot C et al. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 55: 355-60.
49. Springer B, Calligaris-Maibach RC, Ritter C et al. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping. J ClinMicrobiol 2008; 46: 4064-7.
50. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-60.
51. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.